Therapy, Not Tablets: The Real Picture of Cannabis Addiction Treatment
The most comprehensive scientific review of its kind has found that no medication works for cannabis addiction treatment, while certain talking therapies offer more meaningful promise. The findings come from the journal Addiction, published in 2026, at a time when cannabis use disorder is rising worldwide and treatment demand is outpacing the evidence to support it.
Global incidence of cannabis use disorder grew by 32.3% between 1990 and 2019. Prevalence rose by 38.6% over the same period. Yet clinicians still have no approved pharmacological option to offer patients.
What the Researchers Found When Treating Cannabis Use Disorder
A team at the University of Bristol conducted a network meta-analysis (NMA), pooling data from 57 randomised controlled trials with more than 6,200 participants. Unlike a standard review, an NMA lets scientists compare multiple treatments at the same time, including those never directly tested against one another.
The team looked at both psychological (psychosocial) and pharmacological (drug-based) treatments across four key outcomes: cannabis use levels, abstinence, treatment completion, and adverse effects.
Researchers compared psychosocial and pharmacological approaches within one unified analysis for the first time. That makes this the most wide-ranging review of cannabis addiction treatment published to date.
Medications Disappoint
Results for medications were, in a word, disappointing. Across all pharmacological interventions tested, including antidepressants, anticonvulsants, anxiolytics, THC-based preparations and experimental compounds, the evidence for reducing cannabis use or improving abstinence was “highly uncertain.”
Some medications attracted cautious interest. Low-certainty evidence suggested that cannabidiol, N-acetylcysteine and varenicline may increase abstinence compared to placebo. But the confidence intervals in all three cases spanned both meaningful benefit and meaningful harm. No firm conclusions hold.
The safety picture raised further concern. Several medications, including mixed-action antidepressants, benzodiazepines, bupropion and buspirone, produced more adverse events than placebo with no corresponding benefit. The authors stated plainly that pharmacotherapies should still be considered experimental when treating cannabis use disorder.
Therapy Offers More Hope for Cannabis Addiction Treatment
Psychological interventions told a more encouraging story, though still far from definitive. Two approaches stood out.
Dialectical behavioural therapy and acceptance and commitment therapy (DBT/ACT) produced low-certainty evidence of a meaningful reduction in cannabis use frequency. DBT/ACT also showed better treatment completion rates and significantly increased point abstinence in a separate analysis.
Cognitive behavioural therapy combined with contingency management (MET-CBT with CM) also showed reduced use and supported abstinence. Contingency management, where patients receive small financial rewards or vouchers for cannabis-free urine samples, appeared to be the key active ingredient across several effective combinations.
Standalone MET-CBT, long regarded as standard care in many countries, showed little effectiveness and poor treatment completion compared to more structured alternatives. That raises real questions about its current position in clinical pathways.
Why the Evidence Remains Weak
The researchers were candid about gaps in the evidence. Of all findings assessed, 76% carried very low certainty ratings and only 24% reached low certainty. None reached moderate or high certainty.
Several factors drove this. Studies tended to be small, with participant numbers ranging from 10 to 450. Researchers tested many interventions in just a single trial. Missing outcome data, often because participants relapsed and dropped out, created persistent problems. Most psychosocial studies lacked blinding too, meaning participants often knew which treatment they received. That can inflate apparent benefits.
Safety reporting also had notable gaps. Not one psychosocial intervention study recorded adverse events in a way suitable for the safety analysis. That is a significant oversight, particularly since some therapies appeared to lower treatment completion rates.
Who Bears the Biggest Burden
The consequences of cannabis use disorder reach further than many people realise. Young people and adolescents carry a disproportionate burden. Cannabis use links to slower psychomotor speed and poorer attention and memory. Heavy, sustained use associates with lasting neurocognitive deficits into adulthood.
Beyond the individual, cannabis use disorder raises the risk of cardiovascular and respiratory disease and connects to higher all-cause mortality. During adolescence and young adulthood, use correlates with lower educational attainment, reduced income, unemployment, greater economic dependence and higher rates of juvenile offending.
The study participants were predominantly white, male and without significant psychiatric conditions. The researchers pointed out that this limits how far findings apply to the broader population seeking treatment for cannabis use disorder, many of whom live with co-occurring mental health conditions.
What Better Research on Cannabis Addiction Treatment Should Look Like
The authors set out clear recommendations for future work. Trials need larger sample sizes. Researchers and clinicians should agree a core outcome set with input from people with lived experience. Diagnostic criteria need consistency. And psychosocial intervention studies must begin collecting safety data properly.
The authors also called for trials directly comparing psychosocial and pharmacological approaches. Remarkably, that has never happened. Every drug trial in this review ran alongside some form of background psychological support. But no trial has placed both approaches head to head.
Future studies also need to include populations most likely to seek help, particularly people with anxiety, depression, ADHD and other conditions that frequently accompany cannabis use disorder. Since several of the pharmacotherapies reviewed already treat these conditions, integrated trial designs are both feasible and long overdue.
The Bottom Line
This review makes one thing clear. No quick pharmacological fix exists for cannabis addiction treatment right now. Current evidence does not support prescribing any medication for this purpose outside a research setting.
What the evidence does suggest, with low certainty, is that structured psychological approaches, particularly those involving contingency management, DBT or ACT, are more likely to help than harm. They are not a cure. But they are the best tools available today.
Cannabis is becoming more widely used, more potent and more socially accepted across much of the world. The need for robust, evidence-based approaches to treating cannabis use disorder has never been more pressing. This review shows how far the science has come, and how much further it still needs to go.
Source: (WRD News)